louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT04125667: Culture System for Isolating Circulating Tumor cells_2
Official title: Culture System for Isolating Circulating Tumor Cells
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Early Diagnosis
Diagnostic Techniques and Procedures
Keywords: Circulating cancer cells
Biomedical polymer material
Cell affinity difference
White blood cell attachment
Lead sponsor: National Taiwan University Hospital
Sponsor class: OTHER
First posted: 2019-10-14
Enrollment: 45
Sex: ALL
Minimum age (years): 20
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: OTHER
Time perspective: OTHER
Sampling method: NON_PROBABILITY_SAMPLE
Study population: The study population will include all stages of lung cancer patients between the ages of 20 and 70. Also, to protect the vulnerable subjects, we don't recruit minors, prisoners, aborigines, pregnant women, people with mental disorders, students, and subordinates, etc.

Brief summary: This culture system utilizes the special affinity difference of biomedical material coating for different cells to achieve the effect of isolating tumor cells from the blood sample. The coating of the system has the characteristic that to make the WBCs adhesion, but the cancer cells in the blood sample suspend in the culture medium, which achieves the effect of separating cancer cells from the blood. The supernatant with the cancer cells can further be isolated from the cultural system for related analysis and detection to achieve early diagnosis and screening.


Eligibility criteria: Inclusion Criteria:

* Patients with lung cancer are between the ages of 20 and 70
* Willing to sign the consent form under the informed consent

Exclusion Criteria:

* Vulnerable Subjects included minors, prisoners, aborigines, pregnant women, people with mental disorders, students, and subordinates, etc.

Primary outcomes:
measure: The Number of Circulating Cancer Cells from The Blood Sample
timeFrame: about 1 week
Secondary outcomes:
measure: Cancer Cell Isolation Efficiency of The Isolation System
timeFrame: about 1 week
Other outcomes:
Locations:
city: Taipei
country: Taiwan
facility: National Taiwan University Hospital
Study officials:
affiliation: Institute of Biomedical Engineering, National Taiwan University
name: Tai-Horng Young
role: STUDY_CHAIR
References:
Clinical trial NCT01455467: Open-angle Glaucoma Subjects on One Topical Hypotensive Medication Randomized to Treatment With One or Two Trabecular Micro-bypass Stents in Conjunction With Cataract Surgery
Official title: A Prospective Evaluation of Open-angle Glaucoma Subjects on One Topical Hypotensive Medication Randomized to Treatment With One or Two Trabecular Micro-bypass Stents in Conjunction With Cataract Surgery
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Open-angle Glaucoma
Keywords: Open angle glaucoma
Pigmentary glaucoma
Pseudoexfoliative glaucoma
Lead sponsor: Glaukos Corporation
Sponsor class: INDUSTRY
First posted: 2011-10-20
Enrollment: 79
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Evaluation of intraocular pressure (IOP) lowering effect of one iStent versus two iStents in conjunction with cataract surgery in subjects with primary open-angle glaucoma, washed out of one anti-glaucoma medication prior to stent implantation.


Eligibility criteria: Inclusion Criteria:

* Phakic study eye requiring cataract removal and posterior chamber intraocular lens (PC-IOL) implantation
* Primary open-angle glaucoma (including pigmentary or pseudoexfoliative)

Exclusion Criteria:

* Aphakic or pseudophakic with posterior or anterior chamber IOLs (PC-IOLs or AC-IOLs) (study eye)
* Prior stent implantations (study eye)

Primary outcomes:
measure: Mean diurnal IOP reduction of ≥ 20% vs. baseline mean diurnal IOP
timeFrame: 12 Months
Secondary outcomes:
Other outcomes:
Locations:
city: Yerevan
country: Armenia
facility: S.V. Malayan Ophthalmological Center
Study officials:
affiliation: S.V. Malayan Ophthalmological Center, Yerevan, Armenia
name: Lilit A Voskanyan, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02394067: Magnetic Resonance Venography Pre- and Post-Treatment in Patients With Idiopathic Intracranial Hypertension
Official title: Magnetic Resonance Venography Pre- and Post-Treatment in Patients With Idiopathic Intracranial Hypertension
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Pseudotumor Cerebri
Lead sponsor: Nova Scotia Health Authority
Sponsor class: OTHER
First posted: 2015-03-20
Enrollment: 5
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Participants will be recruited from the neuro-ophthalmology service at the Queen Elizabeth II Health Center. Neuro-ophthalmology service in Nova Scotia sees approximately 20 new diagnoses of IIH per year.

Brief summary: This prospective study will use magnetic resonance imaging of patients with Idiopathic Intracranial Hypertension (IIH), to determine if the common radiological finding of transverse venous sinus stenosis can be reversed with standard of care medical treatment of IIH.

Detailed description: Patients with suspected Idiopathic Intracranial Hypertension (IIH) will be recruited and undergo an ophthalmologic investigation, and a lumbar puncture, both of which are necessary for diagnosis of IIH. MRI is done as a standard of care to rule out other etiologies of raised intracranial pressure. Our patients will require four MRI/MRVs. The first MRI/MRV is standard of care scan. The second MRI/MRV will be on the day of the lumber puncture, immediately following the procedure. The third MRI/MRV will take place when significant reduction of clinical papilledema has taken place (about 3-6 months), and a forth MRI will take place one year after the initial presentation or with symptom resolution, whichever comes first. Radiological findings will be compared at all stages to determine if transverse venous sinus stenosis can be reversed with standard of care medical treatment.

Eligibility criteria: Inclusion Criteria:

All patients with a diagnosis of IIH, where other intracranial pathology has been ruled out, can participate.

Exclusion Criteria:

(1)Patients who have a contraindication or are unable to undergo magnetic resonance imaging. (2)Patients who are found to have intracranial pathology to explain elevated intracranial pressure. (3)Patients with allergies to gadolinium-containing agents.(4)Patients with elevated creatinine above normal laboratory values.

Primary outcomes:
measure: Transverse venous sinus stenosis (combined conduit score, and measure of transverse venous sinus stenosis, for each MRI/MRV)
timeFrame: 4 MRI/MRV's performed within a year of diagnosis
Secondary outcomes:
Other outcomes:
Locations:
city: Halifax
country: Canada
facility: CapitalDHACanada
state: Nova Scotia
Study officials:
affiliation: Capital Health, Canada
name: Jai Shankar, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02524067: Modified Environment for Agitation in Patients With TBI
Official title: Modified Environment for Agitation in Patients With Traumatic Brain Injury: a Controlled Multicenter
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Traumatic Brain Injury (TBI)
Agitated Behaviour
Lead sponsor: University of Aarhus
Sponsor class: OTHER
Collaborators: name: Aarhus University Hospital
name: Regionshospitalet Hammel Neurocenter
name: Rigshospitalet, Denmark
name: Glostrup University Hospital, Copenhagen
First posted: 2015-08-14
Enrollment: 20
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: SUPPORTIVE_CARE

Brief summary: This study examines the effect of an intervention consisting of dynamic circadian light and sound therapy, as well as systematic information on sleep pattern, agitated behavior and functioning level.


Eligibility criteria: Inclusion Criteria:

* Patients with moderate and severe Traumatic Brain Injury (TBI)
* Diagnosed with Glasgow Coma Score (GCS) lower than 13-

Exclusion Criteria:

* Patients with psychiatric diagnose and not speaking danish -

Primary outcomes:
measure: Agitation on Agitated Behaviour Scale (ABS)
timeFrame: One year
measure: Functional abilities on the Early Functional Abilities Scale (EFA)
timeFrame: One year
measure: Functional abilities on the Glasgow Outcome Extend Scale
timeFrame: 12 month after admission
Secondary outcomes:
measure: Orientation and duration of post-traumatic amnesia on the Galveston Orientation and Amnesia Scale (GOAT)
timeFrame: One year
Other outcomes:
Locations:
city: Aarhus
country: Denmark
facility: Leanne Langhorn
state: Region Midt
Study officials:
affiliation: Aarhus University Hoapital
name: Jens Christian H Sorensen, Professor
role: STUDY_CHAIR
References:
Clinical trial NCT05781867: Selective Manual Therapy Techniques in Chronic Obstructive Pulmonary Disease
Official title: Effect of Selective Manual Therapy Techniques in Chronic Obstructive Pulmonary Disease
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Chronic Obstructive Pulmonary Disease
Lead sponsor: Cairo University
Sponsor class: OTHER
First posted: 2023-03-23
Enrollment: 52
Sex: MALE
Minimum age (years): 50
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Our study aiming for determining the combined effect of selective manual therapy techniques in chronic obstructive pulmonary disease patients

Detailed description: I will apply selective manual therapy techniques in form of mobilization techniques ,myofascial release techniques combined with traditional treatment to determine thier effect in chronic obstructive pulmonary disease patients

Eligibility criteria: Inclusion Criteria:

* All patients must diagnosed mild to moderate chronic obstructive pulmonary disease
* All patients should have foreward head and kyphosis

Exclusion Criteria:

* History of osteoporosis.
* Acute exacerbation.
* Presence of active hemoptysis
* Presence of malignant disease

Primary outcomes:
measure: chest expansion
timeFrame: pre-intervention and after 8 weeks of intervention
measure: (the forced vital capacity (FVC), forced expiratory volume at first second (FEV1) and FEV1/FVC will be recorded. )
timeFrame: pre-intervention
measure: cranio-vertebral angle and kyphotic angle in degrees
timeFrame: pre-intervention
measure: functional capacity.
timeFrame: pre-intervention
measure: dyspnea score
timeFrame: pre-intervention
Secondary outcomes:
Other outcomes:
Locations:
city: Giza
country: Egypt
facility: Cairo University
Study officials:
References:
Clinical trial NCT04402567: Impact and Burden of Rugby Injuries in Argentina. A Complete Season Retrospective Multicentric Study.
Official title: "Showing the Truth": Impact and Burden of Rugby Injuries in Argentina. A Complete Season Retrospective Multicentric Study.
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Injuries
Keywords: epidemiology
Incidence
Injury severity
Football
Lead sponsor: Hospital Donación Francisco Santojanni
Sponsor class: OTHER
First posted: 2020-05-27
Enrollment: 250
Sex: MALE
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: OTHER
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Male Argentine amateur rugby players of the 2019 season

Brief summary: The aim of this study was to describe the prevalence, incidence and injury load suffered in male amateur rugby players from Argentina during a competitive season in 2019.

Detailed description: Introduction:

Currently, Rugby is a sport that is giving priority to the well-being of the player. Players are subjected to high training and match loads exposing them to constant stress that can lead to overload injuries in addition to frequent contact injuries. Despite knowing what the situation is like at the international and national level, the "Unión Argentina de Rugby" lacks conclusive epidemiological data.

Our main purpose was to describe the prevalence, incidence and injury load suffered in male amateur rugby players from Argentina during a competitive season in 2019.

Design:

Observational, descriptive, retrospective and multicenter study.

Participants:

250 male amateur rugby players belonging to three clubs from three rugby unions (Buenos Aires, Córdoba and Rosario) of Argentina.

Methods:

Registration methods were applied according to the consensus of the World Rugby by a single observer per center. Injuries occurred in players from top rosters of 3 amateur rugby clubs (data collection centers) as well as the number of matches and hours of training were recorded. Medical diagnoses were classified under the rules of the OSIICS classification system. The incidence (injuries / 1000 hours-game-player), prevalences (point and period), the severity (days of absence) and the injury load will be calculated as well as the location, type, nature. This study followed the guidelines of the STROBE-SIIS Initiative Declaration.

Eligibility criteria: Inclusion Criteria:

* \>18 years
* Participation in more than 80% during training and matches of the competitive season.
* First, intermediate, Pre-intermediate A and Pre-intermediate B categories of the University teams of Córdoba, Old Resian and Los Matreros, belonging to UAR member unions.

Exclusion Criteria:

- Lost patient data

Primary outcomes:
measure: Injury Incidence
timeFrame: 9 months
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: Hospital Donación Francisco Santojanni
name: Mauro Andreu, BSc
role: STUDY_DIRECTOR
References:
Clinical trial NCT03141567: LYmphangiogenesis FacTors in Heart Failure States
Official title: LYmphangiogenesis FacTors in Heart Failure States (LYFT-HF Study)
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Heart Failure
Heart Failure With Reduced Ejection Fraction
Heart Failure With Normal Ejection Fraction
Keywords: Lymphangiogenesis
Heart Failure
Lead sponsor: Medical University of South Carolina
Sponsor class: OTHER
First posted: 2017-05-05
Enrollment: 100
Sex: ALL
Minimum age (years): 18
Maximum age (years): 99
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: OTHER
Time perspective: OTHER
Sampling method: NON_PROBABILITY_SAMPLE
Study population: All Inpatient and Outpatient individuals undergoing clincially-indicated right heart catheterization.

Brief summary: Heart failure often causes fluid to accumulate in the body, leading to congestion and swelling. However, some people who have had heart failure for a long time seem to have very little congestion or swelling, even when the heart failure is poorly treated. The investigators think that this is because lymphatic vessels are able to grow and remove fluid to prevent congestion. The investigators do not know how lymphatic vessels grow. This study will investigate the blood levels of various proteins to try to figure out how the lymph vessels of people with long-standing heart failure might grow.


Eligibility criteria: Inclusion Criteria:

* Undergoing clinically indicated right heart catheterization.

Exclusion Criteria:

* Unable to provide consent.
* Use of medications which may alter lymphangiogenesis factor expression within 365 days
* Thalidomide, lenalidomide, pomalidomide
* Bevacizumab
* Any cytotoxic chemotherapy agents
* Pregnant
* Any potentially pregnant patient (based on age and gender) undergoes Beta Human chorionic gonadotropin testing as standard of care prior to any right heart catheterization.
* Active cancer within 365 days
* Diagnosis of familial or secondary lymphedema
* Treatment of active bacterial infection within 7 days
* Active inflammatory rheumatologic disease requiring anti-inflammatory therapy administration within 60 days
* Conditions
* Systemic lupus erythematosus
* Rheumatoid arthritis
* Scleroderma
* Inflammatory myositis
* Vasculitis
* Behcet's disease

Primary outcomes:
measure: Vascular Endothelial Growth Factor (VEGF) Levels
timeFrame: At time of right heart catheterization
Secondary outcomes:
measure: Lymphangiogenesis factors and Pulmonary Capillary Wedge Pressure (PCWP)
timeFrame: At time of right heart catheterization
measure: Lymphangiogenesis and Heart failure severity
timeFrame: At time of right heart catheterization
measure: Lymphangiogenesis and 6 minute hall walk
timeFrame: At time of right heart catheterization
Other outcomes:
Locations:
city: Charleston
country: United States
facility: Ralph H. Johnson VAMC
state: South Carolina
city: Charleston
country: United States
facility: Medical University of South Carolina
state: South Carolina
Study officials:
affiliation: Assistant Professor
name: Brian Houston, M.D.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04602767: Low Dose Vasopressin vs Phenylephrine in Cardiac Surgery
Official title: Low Dose Vasopressin vs Phenylephrine in Cardiac Surgery
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: PHASE4
Conditions: Acute Kidney Injury
Lead sponsor: Thomas Jefferson University
Sponsor class: OTHER
First posted: 2020-10-26
Enrollment: 300
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: This is a randomized, open label study to investigate vasopressin versus phenylephrine as a first line pressor in cardiac surgery. All patients \>18 years of age presenting for coronary artery bypass graft (CABG), valve surgery, or combined CABG and valve surgery will be screened for inclusion. Patients with ejection fraction \< 35%, \> moderate pulmonary hypertension, \> mild right ventricular dysfunction, a planned radial arterial graft, or circulatory arrest will be excluded. Patients will be randomized to receive either vasopressin or phenylephrine as the first line vasopressor during the perioperative period to maintain mean arterial blood pressure \>65 mmhg. Primary outcome is acute kidney injury. Secondary outcomes are 30-day mortality, stroke, myocardial infarction, re-operation, sternal infection, atrial fibrillation, intensive care unit length of stay, and total vasopressor hours.


Eligibility criteria: Inclusion Criteria:

* \>18 years of age
* Coronary artery bypass graft (CABG), valve, or combined CABG and valve surgery

Exclusion Criteria:

* Ejection fraction \< 35%
* \> moderate pulmonary hypertension
* \> mild right ventricular dysfunction
* Radial arterial graft
* Circulatory arrest

Primary outcomes:
measure: Number of patients with acute kidney injury
timeFrame: 5 Days
Secondary outcomes:
measure: Number of patients with 30-Day Mortality
timeFrame: 30 Days
measure: Number of patients with reoperation
timeFrame: 5 Days
measure: Number of patients with sternal Infection
timeFrame: 5 Days
measure: Number of patients with Atrial Fibrilation
timeFrame: 5 Days
measure: ICU Length of Stay
timeFrame: 5 Days
measure: Total Vasopressor Hours
timeFrame: 5 Days
Other outcomes:
Locations:
city: Philadelphia
country: United States
facility: Thomas Jefferson Univesity
state: Pennsylvania
Study officials:
References:
Clinical trial NCT01437267: Safety and Immunogenicity of Vi-CRM197 Vaccine Against S. Typhi in Children, Older Infants and Infants
Official title: A Phase 2, Randomized, Controlled, Observer Blind, Single Center Study of the Safety, Reactogenicity and Immunogenicity of the NVGH Glycoconjugate Vaccine Against S. Typhi in Children, Older Infants and Infants
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Typhoid Fever
Lead sponsor: Novartis
Sponsor class: INDUSTRY
First posted: 2011-09-20
Enrollment: 120
Sex: ALL
Minimum age (years): 6
Maximum age (years): 59
Standard ages: CHILD
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: This phase 2 trial is aimed to obtain information on the safety and immunogenicity of the Vi-CRM197 in children and infants from various age groups in the Philippines where Typhoid Fever is highly endemic and an efficacious vaccine against this disease is very much needed.


Eligibility criteria: Inclusion criteria:

* Subjects belonging to 3 age groups will be enrolled into the trial: children (24 to 59 months of age at enrollment), older infants (9 to 12 months of age at enrollment) and infants (6 weeks of age at enrolment).
* Written informed consent will be obtained by the parents/ guardians before enrollment into the trial.
* Infants who have been vaccinated with BCG and HBV at birth and OPV at any time since birth can be enrolled into the trial, while infants who have received DTwP+HBV+Hib due at 6 weeks of age as per local EPI schedule cannot be enrolled into the trial.

Primary outcomes:
measure: Percentage of Subjects With at Least 4-fold Increase in Anti-Vi Enzyme-linked Immunosorbent Assay (ELISA) Titer
timeFrame: At 28 days after last vaccination as compared to baseline
measure: Percentage of Subjects With at Least 4-fold Increase in Anti-Vi ELISA Titer
timeFrame: At 6 months after last vaccination as compared to baseline
measure: Anti-Vi ELISA Geometric Mean Concentration (GMC)
timeFrame: At 28 days after last vaccination
measure: Anti-Vi ELISA GMC
timeFrame: At 6 months after last vaccination
Secondary outcomes:
measure: Number of Participants With Any Solicited Local and Systemic Reaction, After Any Vaccination
timeFrame: During the 7-day follow-up period after vaccination
Other outcomes:
Locations:
city: Alabang, Muntinlupa City
country: Philippines
facility: Research Institute for Tropical Medicine (RITM)
Study officials:
affiliation: Research Institute for Tropical Medicine (RITM)
name: Maria Rosario Z Capeding, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Bhutta ZA, Capeding MR, Bavdekar A, Marchetti E, Ariff S, Soofi SB, Anemona A, Habib MA, Alberto E, Juvekar S, Khan RM, Marhaba R, Ali N, Malubay N, Kawade A, Saul A, Martin LB, Podda A. Immunogenicity and safety of the Vi-CRM197 conjugate vaccine against typhoid fever in adults, children, and infants in south and southeast Asia: results from two randomised, observer-blind, age de-escalation, phase 2 trials. Lancet Infect Dis. 2014 Feb;14(2):119-29. doi: 10.1016/S1473-3099(13)70241-X. Epub 2013 Nov 28.